Compare Medtronic PLC (MDT) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Otis Worldwide Corp — how do they compare? Medtronic PLC trades at $82.31 (market cap $106.61B), while Otis Worldwide Corp trades at $72.22 (market cap $28.20B). The key difference: Medtronic PLC is far larger — about 3.8× Otis Worldwide Corp's market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| MDT | OTIS | |
|---|---|---|
Market Cap | $106.61B | $28.20B |
Sector | Health | Industrials |
52-Week High | $105.35 | $100.99 |
52-Week Low | $73.75 | $69.34 |
Enterprise Value | $125.36B | $35.58B |
Dividend Yield | 3.46% | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $82.35, down 1.02% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.39. Revenue grew to $33.54B in 2025, with a net income margin of 13.2%. Recent news highlights the acquisition of SPR and the launch of AI-powered surgical technology, signaling innovation-driven growth.
The outlook for MDT is positive, supported by analyst consensus with a $97.50 price target and 58% buy ratings. Key opportunities include robust cash flow and dividend stability, while risks involve rising debt levels and competitive pressures in medtech. The stock presents a value proposition with a P/E of 22.33, trading below the consensus target.
Otis Worldwide (OTIS) trades at $71.95, down 2.04% recently, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed Q1 2026 earnings, missing EPS estimates but showing strong service growth. Revenue trends are stable, with 2025 revenue at $14.43B and net income of $1.38B. Analyst consensus is a Buy with a $91.00 price target, implying significant upside. Recent news highlights modernization initiatives and Q2 earnings focus.
The outlook for OTIS is cautiously optimistic, with potential driven by service segment strength and strategic upgrades, but risks include margin pressures from tariffs and economic headwinds. Valuation at a P/E of 19.54 is reasonable, yet debt levels and recent earnings misses warrant monitoring. Institutional sentiment is mixed, with 38% Buy ratings offset by high debt-to-asset ratio of 75.54% as of 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
